Log in

NASDAQ:RTRXRetrophin Stock Price, Forecast & News

-0.75 (-4.31 %)
(As of 05/26/2020 04:00 PM ET)
Today's Range
Now: $16.66
50-Day Range
MA: $15.60
52-Week Range
Now: $16.66
Volume179,500 shs
Average Volume420,250 shs
Market Capitalization$718.98 million
P/E RatioN/A
Dividend YieldN/A
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase II clinical trial for the treatment of phenylketonuria; and liquid ursodeoxycholic acid, a liquid formulation of ursodeoxycholic acid for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Read More
Retrophin logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RTRX



Sales & Book Value

Annual Sales$175.34 million
Book Value$5.15 per share


Net Income$-146,430,000.00


Market Cap$718.98 million
Next Earnings Date8/4/2020 (Estimated)

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

How has Retrophin's stock been impacted by COVID-19 (Coronavirus)?

Retrophin's stock was trading at $14.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RTRX shares have increased by 12.6% and is now trading at $16.66. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Retrophin?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Retrophin.

When is Retrophin's next earnings date?

Retrophin is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Retrophin.

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) issued its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.70. The biopharmaceutical company had revenue of $47.77 million for the quarter, compared to analyst estimates of $43.14 million. Retrophin had a negative net margin of 57.01% and a negative return on equity of 43.15%. View Retrophin's earnings history.

What price target have analysts set for RTRX?

7 equities research analysts have issued 12-month price targets for Retrophin's shares. Their forecasts range from $19.00 to $34.00. On average, they expect Retrophin's stock price to reach $28.50 in the next twelve months. This suggests a possible upside of 71.1% from the stock's current price. View analysts' price targets for Retrophin.

Has Retrophin been receiving favorable news coverage?

News stories about RTRX stock have trended negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Retrophin earned a news impact score of -2.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutRetrophin.

Who are some of Retrophin's key competitors?

What other stocks do shareholders of Retrophin own?

Who are Retrophin's key executives?

Retrophin's management team includes the following people:
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
  • Dr. William E. Rote, Sr. VP and Head of R&D (Age 56)
  • Dr. Noah L. Rosenberg, Chief Medical Officer (Age 52)
  • Dr. Eric M. Dube Ph.D., Pres, CEO & Director (Age 46)

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

Who are Retrophin's major shareholders?

Retrophin's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.65%), The Manufacturers Life Insurance Company (5.43%), State Street Corp (4.00%), Nuveen Asset Management LLC (1.30%), Assenagon Asset Management S.A. (1.00%) and Deutsche Bank AG (0.97%). Company insiders that own Retrophin stock include Elizabeth E Reed, Eric M Dube, Laura Clague, Neil F Mcfarlane, Noah L Rosenberg, Steve Aselage and William E Rote. View institutional ownership trends for Retrophin.

Which institutional investors are selling Retrophin stock?

RTRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, RA Capital Management L.P., DRW Securities LLC, WINTON GROUP Ltd, Wells Fargo & Company MN, Legal & General Group Plc, and UBS Group AG. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Eric M Dube, Laura Clague, Noah L Rosenberg, Steve Aselage, and William E Rote. View insider buying and selling activity for Retrophin.

Which institutional investors are buying Retrophin stock?

RTRX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Janus Henderson Group PLC, GW&K Investment Management LLC, Atom Investors LP, AXA, Russell Investments Group Ltd., Dupont Capital Management Corp, and BNP Paribas Arbitrage SA. View insider buying and selling activity for Retrophin.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $16.66.

How big of a company is Retrophin?

Retrophin has a market capitalization of $718.98 million and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. Retrophin employs 214 workers across the globe.

What is Retrophin's official website?

The official website for Retrophin is www.retrophin.com.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.